Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448440 | 0.90 | MEN1 (0.44) | ALDH1A1MAPK10KMT2AMEN1PDE4A | |
| SCHEMBL3975612 | 0.88 | MAPT (0.43) | ALDH1A1KMT2AMEN1PDE4APDE4B | |
| SCHEMBL3980428 | 0.83 | GAA (0.40) | MAPK10KMT2AMEN1PDE4APDE4B | |
| SCHEMBL449975 | 0.81 | HDAC1 (0.61) | HDAC1HDAC6HDAC2 | |
| SCHEMBL436167 | 0.81 | MEN1 (0.42) | ALDH1A1MAPK10KMT2AMEN1ENPP2 | |
| SCHEMBL3974440 | 0.80 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL10145490 | 0.77 | MEN1 (0.44) | ALDH1A1KMT2AMEN1PDE4APDE4B | |
| SCHEMBL3972272 | 0.77 | CA1 (0.38) | ALDH1A1PTPN1 | |
| SCHEMBL743176 | 0.77 | LMNA (0.45) | ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3973411 | 0.76 | CNR2 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| EP-0002895-B1 | ENZYME INHIBITORY PHTHALAZIN-4-YLACETIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESS FOR THEIR MANUFACTURE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-10-14 | — | — | EP | claimed |
| US-4251528-A | ALDOSE REDUCTASE INHIBITORS USEFUL IN DIABETES, GALACTOSEMIA | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-02-17 | — | — | US | claimed |
| EP-0002895-A1 | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-07-11 | — | — | EP | claimed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8716326-B2 | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-05-06 | — | — | US | disclosed |
| US-8716326-B2 | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-05-06 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| EP-2509602-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-4203802-A | ENZYME BOUND TO AN ESTROGEN LIGAND | SYVA COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4190496-A | RECEPTOR, LIGAND, AND ENZYME-BOUND | SYVA COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
| EP-0002895-A1 | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-07-11 | — | — | EP | disclosed |
| US-4067774-A | Compounds for enzyme amplification assay | SYVA COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-3975237-A | LIGANDS | SYVA COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3966556-A | Compounds for enzyme amplification assay methadone analogs | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966744-A | Spin labeled compounds | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3959287-A | Ligand determination of spin labeled compounds by receptor displacement | SYVA COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | ALDH1A1 3161/4885MAPK10 2608/4885KMT2A 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.